YM BioSciences Terminates Phase III Breast Cancer Trial
This article was originally published in The Pink Sheet Daily
Future of separate program involving tesmilifene in combination with Sanofi-Aventis’ Taxotere remains uncertain, company says.
You may also be interested in...
Enrollment in a European Phase III trial for the mAb as a first-line treatment for pediatric diffuse intrinsic pontine glioma has initiated.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.